# Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

> **NCT02520102** · PHASE2 · WITHDRAWN · sponsor: **Sanofi**

## Conditions studied

- Acute Myeloid Leukemia NOS

## Interventions

- **DRUG:** sargramostim GZ402664

## Key facts

- **NCT ID:** NCT02520102
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-02
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company has fulfilled post-marketing requirements
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520102, "Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02520102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*